Asivatrep is a new potential treatment for eczema (atopic dermatitis). Atopic dermatitis is a chronic inflammatory itchy skin disease that affects up to 25% of children and 10% of adults. The cause is complex and multifactorial. Currently there are few classes of topical medications to treat it. Steroids Calcineurin inhibitors (Elidel, Protopic) Phosphodiesterase 4 inhibitors Eucrisa […]
PEG Allergy and Vaccine Allergy
PEG allergy has become an important topic since the COVID-19 vaccine rollout. There are 2 messenger RNA vaccines that have been approved in multiple countries around the world. Pfizer Covid Vaccine and Allergy Moderna Covid Vaccine and Allergy There are 3 adenovirus vector vaccines as well. Johnson and Johnson Covid Vaccine and Allergy Since the vaccine […]
Opzelura (ruxolitinib) for Eczema
Opzelura (ruxolitinib) has been FDA approved for eczema. Opzelura is a topical JAK inhibitor, and its indicated for short term use in patients 12 and up who have mild to moderate atopic dermatitis. It is the first topical janus kinase inhibitor approved in the United States. Currently for atopic dermatitis topical treatment, the mainstay of […]
Nasal Polyps Treatment; Past, Present and Future
Nasal polyps treatment have shown great advances recently, and many more treatments are on the horizon. Nasal polyps are used to describe chronic rhinosinusitis associated with the formation of nasal polyps. Nasal polyps affect 2-4% of adults globally. About 50% of patients have existing allergies. Nasal polyps are semitranslucent, pale grey, grape-like, benign inflammatory lesions […]
Baricitinib for Atopic Dermatitis (Eczema)
Baricitinib is currently being studied for the treatment of atopic dermatitis. Baricitinib is part of the family of oral Janus kinase inhibitors that are an emerging modality in the treatment of chronic allergic inflammatory disorders due to their ability to inhibit signaling of multiple pathways of cytokines. We discussed in another blog post, Abrocitinib which is […]
New Urticaria Treatment Options being studied
New urticaria treatment options are currently being studied for patients with chronic spontaneous urticaria. Currently the only approved biologic medication approved for this condition is Xolair. Several medications are also being used off label and novel biologics are currently in development. Here we discuss them: Dupilumab– In preclinical studies, dupilumab (Dupixent) blocked several functions of […]
Capsaicin for Nonallergic Rhinitis
Capsaicin nasal spray may be an effective treatment for patients who have nonallergic rhinitis. A significant proportion (25-30%) of patients suffering from rhinitis have nasal symptoms without an infection or allergies, this is referred to nonallergic rhinitis. Up to 50% of these patients have idiopathic rhinitis after excluding work, elderly, gustatory, hormonal and drug induced […]
Allegra during Pregnancy, is it safe?
Allegra during pregnancy, is it safe to use? Antihistamines are commonly prescribed to pregnant women. Cetirizine (Zyrtec) and loratadine (Claritin) are considered safe to use during pregnancy, but there are few data on the safety of Allegra (fexofenadine) for the fetus. A study published in the JAMA Pediatrics titled “Association between fexofenadine use during pregnancy […]
Indacaterol for severe asthma
Indacaterol is an ultra long acting beta agonist that is currently only FDA approved to treat COPD. Indacaterol containing inhalers have shown promise in 2 recent phase 3 trials in patients with severe uncontrolled asthma. For both trials, the endpoint was measured on spirometry and it studied the FEV1 after 26 weeks of treatment. In […]
Cibinqo Abrocitinib for Atopic Dermatitis by Pfizer
Cibinqo Abrocitinib is currently being developed by Pfizer for the treatment of atopic dermatitis (eczema). It is an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor. The JAK/STAT pathway is an important factor in inflammation and itch in atopic dermatitis. There are multiple receptors and signaling cascades involved in eczema related inflammation and itch, one […]